MedTrace Logo

18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms

NCT07102056 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 152

Last updated 2025-12-29

No results posted yet for this study

Summary

The study aims to elucidate how 18F-Octreotide PET/CT or PET-MR can assist in accurate localization, treatment planning, prognostic predictions, and the selection of PRRT efficacy in neuroendocrine tumors. It also highlights important applications in lesion segmentation measurement, tumor grading, prognostic survival prediction, and genotype identification.

Conditions

Interventions

DIAGNOSTIC_TEST

18F-AlF-NOTA-Octreotide PET-CT or PET-MR

18F-Octreotide PET/CT or PET/MR And enhanced CT or MR Imaging

Sponsors & Collaborators

  • First Affiliated Hospital of Zhejiang University

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2027-06-03
Completion
2027-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07102056 on ClinicalTrials.gov